Rtw Investments 13F: Adds $225M to Erasca (ERAS) Stake

RTW Investments has made a significant move by boosting its position in ERAS, a notable player in the biotech sector. According to its latest 13F filing with the SEC, RTW increased its holdings by 16,010,524 shares, bringing its total to 16,157,175 shares. This represents a substantial increase of over 10,917%, with the stake valued at approximately $227 million as of the end of the reporting period.

What Changed in RTW Investments' ERAS Position

RTW Investments dramatically increased its stake in ERAS, moving from 146,651 shares to 16,157,175 shares, a change of 16,010,524 shares. This boost reflects a massive 10,917% increase in their holdings, indicating a strong interest in the company's prospects. The value of this position is now approximately $227 million.

Other Institutional Activity in ERAS

Several other institutional investors have also adjusted their positions in ERAS. Frazier Life Sciences Management added 1,945,752 shares, ending with 24,675,188 shares valued at about $399 million. T. Rowe Price Investment Management added 5,148,232 shares, bringing its total to 21,259,646 shares, worth approximately $344 million. BlackRock, Inc. increased its holdings by 4,554,076 shares to a total of 20,151,406 shares, valued at $326 million. Conversely, Venrock Adviser, LLC reduced its position by 1,474,271 shares, now holding 16,382,812 shares valued at around $265 million.

Erasca, Inc. Stock Down 4.9%

Shares of ERAS are currently trading at $14.05. While specific market metrics such as the market cap, P/E ratio, and beta are not provided, the stock's 52-week range and moving averages remain crucial for investors to monitor.

Insider Buying and Selling at Erasca, Inc.

Recent insider activity at ERAS includes transactions by Chief Legal Officer Ebun Garner, who sold and bought 80,000 shares on April 1, 2026, under both planned and non-planned transactions. Chief Medical Officer Shannon Morris also engaged in similar activities, selling and buying 20,000 shares on March 4, 2026.

Analysts Set New Price Targets

Analyst activity remains active for ERAS, with B of A Securities upgrading the stock to a 'hold' rating with a $16 price target on June 4, 2026. Mizuho maintained its 'buy' rating with a $26 target on May 12, while Stifel also kept a 'buy' rating with a $30 target on April 27. Overall, the consensus remains positive, with a strong 'buy' recommendation and varied price targets.

About ERAS

ERAS operates in the biotechnology sector, focusing on innovative treatments and therapies. While detailed company fundamentals such as headquarters location, CEO, and employee count are not disclosed, the company's activities in developing cutting-edge solutions make it a significant player in its industry.

Bottom Line

RTW Investments' massive increase in ERAS holdings underscores a strong belief in the company's potential. This move, part of a backward-looking 13F filing, reflects RTW's strategic positioning as of the end of the reporting period. As always, investors should consider this alongside broader market conditions and other institutional activities.